Welcome to our dedicated page for Lixte Biotechnology Hldgs news (Ticker: LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Hldgs stock.
Lixte Biotechnology Holdings, Inc. reports clinical-stage oncology developments centered on LB-100, its proprietary first-in-class PP2A inhibitor. Recurring updates describe proof-of-concept work in ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma, including combination studies with immunotherapy and other cancer-treatment approaches.
The company also issues news on its broader cancer-treatment platform, including Liora Technologies Europe, radiotherapy technology, patent coverage, trial-site and collaborator activity, capital raises, annual-report highlights, executive and board changes, and investor-conference participation. Its public updates frame LIXT as a clinical-stage pharmaceutical and med-tech issuer focused on new targets for cancer drug development.
Lixte Biotechnology Holdings (Nasdaq: LIXT) announced that the National Cancer Institute has resumed patient enrollment for a study evaluating LB-100's ability to penetrate malignant brain tumors. This follows a suspension due to COVID-19. The study aims to enroll up to 20 patients, with an initial goal of obtaining pharmacologic data from 8. If successful, it could pave the way for larger trials examining LB-100's impact on treatment outcomes for glioblastoma, a challenging cancer to treat. CEO Dr. John S. Kovach emphasized the potential of LB-100 to enhance existing therapies.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) will present at the Benzinga Global Small Cap Conference on October 28, 2021. CEO John S. Kovach, M.D., will discuss the lead clinical compound, LB-100, a PP2A inhibitor, and its collaboration with the Netherlands Cancer Institute and Oncode Institute. This partnership aims to identify effective drug combinations and new targets for LB-100 in cancer treatment. Pre-clinical studies led by Professor René Bernards will utilize genome-wide functional genetic techniques to enhance treatment efficacy.
Lixte Biotechnology Holdings has announced a collaboration with the Netherlands Cancer Institute and Oncode Institute to explore drug combinations with their lead compound, LB-100. This initiative aims to enhance cancer treatment efficacy by identifying promising drug pairings and understanding the underlying molecular mechanisms. Pre-clinical studies, led by noted researcher Professor René Bernards, will utilize innovative genetic techniques to select effective drug combinations, potentially improving outcomes for patients.
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced promising results from recent pre-clinical studies of its lead compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor. The studies indicate that LB-100 may effectively reduce behavioral sensitization related to methamphetamine addiction, potentially opening avenues for future clinical trials. The company is currently focused on highly aggressive cancers, with LB-100 involved in clinical studies for conditions such as myelodysplastic syndromes and small cell lung cancer. The total addressable market for these cancer types exceeds $5 billion.
Lixte Biotechnology Holdings has announced promising results from a pre-clinical study indicating that its lead compound LB-100 enhances the efficacy of standard therapies in small cell lung cancer (SCLC). The findings underpin a recently initiated Phase 1b clinical trial at City of Hope, exploring the combination of LB-100 with carboplatin, etoposide, and atezolizumab.
LB-100 was found to increase drug uptake in tumor cells without raising toxicity, supporting its potential as a transformative treatment for aggressive cancers.
On July 22, 2021, Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced positive pre-clinical research findings regarding its lead compound, LB-100. The study revealed that LB-100, when combined with BioMarin's vosoritide, significantly enhanced bone growth in a mouse model of achondroplasia, surpassing the effects of vosoritide alone. CEO John S. Kovach highlighted LB-100's potential for treating small cell lung cancer and advanced soft tissue sarcomas, emphasizing its unique status as the only PP2A inhibitor in clinical trials. Lixte aims to demonstrate LB-100's clinical benefits across various serious diseases.
Lixte Biotechnology Holdings, Inc. announced recognition for Julio Pimentel, a doctoral student, for his research on LB-100 in triple negative breast cancer (TNBC). Pimentel was awarded the National Latino Leader Award and a scholarship to present his findings at a conference in October 2021. His research showed that LB-100 effectively inhibits TNBC cells and enhances the effectiveness of standard chemotherapy drugs like paclitaxel and cisplatin. Lixte's CEO highlighted the potential of LB-100 as a novel therapeutic approach for TNBC, which represents 15-20% of breast cancer cases in the U.S.
Lixte Biotechnology Holdings (Nasdaq: LIXT) is set to present at the MoneyShow July Virtual Expo from July 13-15, 2021. The event is accessible to the public and will feature a presentation by CEO John S. Kovach, M.D., outlining the Phase 1b/2 clinical trial for the lead compound LB-100, targeting extensive stage small cell lung cancer. This innovative trial is conducted in partnership with the City of Hope. Lixte is committed to developing effective cancer therapies and has achieved promising results with its PP2A inhibitor.
On June 2, 2021, Lixte Biotechnology Holdings announced the enrollment of the first patient in a Phase 1b clinical trial for LB-100, a PP2A inhibitor, in combination with chemotherapy for extensive stage small cell lung cancer (ED-SCLC). The trial, conducted at City of Hope, aims to assess the therapeutic benefit of LB-100 alongside carboplatin, etoposide, and atezolizumab. Preclinical data suggests that LB-100 enhances chemotherapy effectiveness in animal models. Approximately 30,000 new cases of small cell lung cancer are diagnosed annually in the U.S., highlighting the urgent need for effective treatments.
Lixte Biotechnology Holdings, Inc. has appointed Regina Brown, CPA, as an independent director and audit committee chair. Her extensive experience in public accounting, compliance, and taxation is seen as a valuable asset as the company expands. Brown has over 30 years of experience working with a diverse clientele, including large corporations and those with international operations. This appointment is expected to enhance Lixte's governance and oversight.